Fluoroscopy Reduction or Elimination in CIED Implants

Sponsor
Université de Sherbrooke (Other)
Overall Status
Recruiting
CT.gov ID
NCT04919733
Collaborator
(none)
150
1
1
50
3

Study Details

Study Description

Brief Summary

CIED implants require different amounts of fluoroscopy; using 3-D mapping systems, these times could be reduced to near zero fluoroscopy. The investigators aim to describe to what extent fluoroscopy times are reduced on a routine basis on CIED implants

Condition or Disease Intervention/Treatment Phase
  • Device: Fluoroscopy reduction
N/A

Detailed Description

Patients with either brady arrhythmias, tachyarrhythmias, heart failure or primary prevention of sudden death receive a cardiac implantable electronic device (CIED) as a standard of care based on guideline indications. All implants require X-ray equipment to visualize the advancement and positioning of leads in different heart chambers. To date only anecdotical cases have been reported in the literature, of implants without fluoroscopy, mostly pregnant patients with a CIED indication that could not wait for implant after delivery or some rare situations where ultrasound was used to guide the leads trough the heart.

There are two reported experiences using St-Jude Abbot 3-D NavX system; where 35 (ICD and pacemakers) and 15 (VVI pacemakers only) CIED patients were respectively approached with times reported to right ventricular lead implant of 18 +/- 22 minutes and atrial lead implant of 16 +/- 9 minutes, in 89% of cases a final fluoroscopy shot was deemed necessary (in 16% of patients it was needed to correct final position); in the second report with VVI only pacemakers, the implant of a single lead was 10.1 +/- 5.4 minutes, and the total procedure duration was 59.3 +/- 15.16 minutes -one patient needed fluoroscopy-, this last cohort was compared to previous 15 VVI pacemaker patients implanted under fluoroscopy, with control times of 51.5 +/- 12.3 minutes6 (p=ns); both studies reported around 10 minutes needed to obtain right chamber anatomies. There is a little more experience on biventricular implants with two reports one single center and then the same Italian group with a multicenter study achieving a significant reduction in fluoroscopy times: from 16 minutes to 4 minutes (ranges from 11-26 to 0.3-10.4 minutes) compared with a historical control, and with the same success rates to left lead implants; even in experienced centers (more than 10 previous implants) the median time was 3 minutes of fluoroscopy when a St-Jude Abbot NavX system was used.

The advancement on 3-D mapping systems, allows nowadays to reduce and even eliminate the need of X-rays for most of ablation procedures, where the catheters advancement, positioning and navigation through the four heart chambers is accomplished with minimal or no irradiation to the patients and to the health care personnel.

The hypothesis is that use of standard 3-D mapping systems to achieve CIED implants is feasible, safe, and that could be accomplished in a time efficient way. This will be the first large report for all type of CIED implants and with all available 3-D mapping system utilization; the investigators will try also to define if a complete reconstructed virtual anatomy is needed of if a rough anatomy is sufficient to achieve the implant, and speed procedure times.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
To ascertain if the use of 3-D mapping systems reduces the need of fluoroscopy during a CIED (pacemaker or defibrillator) implantTo ascertain if the use of 3-D mapping systems reduces the need of fluoroscopy during a CIED (pacemaker or defibrillator) implant
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Fluoroscopy Reduction or Elimination in CIED Implants
Actual Study Start Date :
Jan 3, 2020
Anticipated Primary Completion Date :
Jan 3, 2024
Anticipated Study Completion Date :
Mar 3, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Non fluoroscopy CIED implant

Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system

Device: Fluoroscopy reduction
To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED

Outcome Measures

Primary Outcome Measures

  1. Fluoroscopy time needed to implant a CIED while using 3-D mapping systems to reduce fluoroscopy exposure [During implant procedure]

    Fluoroscopy time while implanting a CIED

  2. Peak skin dose of radiation exposure during CIED implant [During implant procedure]

    Radiation exposure expressed as total Cumulative Air Kerma (mGy)

  3. Radiation exposure (kerma-area product) during CIED implant [During implant procedure]

    Total Dose Area Product (uGy-m2)

  4. Total procedural time [During implant procedure]

    Time of the patient entering the lab, to the time the patient exits the lab

  5. Safety issues arising because of reduction of fluoroscopy [During implant procedure]

    Complications arising while using a reduced fluoroscopy environment

Secondary Outcome Measures

  1. Detailed 3-D mapping needed Y/N [During implant procedure]

    Is it necessary to create a detailed anatomy to navigate leads without fluoroscopy

  2. Current of lesion at desired implant fixation site (Y/N) [During implant procedure]

    If current of lesion is necessary to ascertain that the fixation mechanism is already deployed

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • CIED implants
Exclusion Criteria:
  • Patients with an urgent life-threatening indication requiring an urgent CIED implant.

  • Patients with known venous system abnormalities (as venous occlusion or abandoned non-accessible leads).

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHUS Fleurimont Sherbrooke Quebec Canada J1H 5N4

Sponsors and Collaborators

  • Université de Sherbrooke

Investigators

  • Principal Investigator: Felix AYALA PAREDES, MD, PhD, University of Shebrooke Medical School

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Université de Sherbrooke
ClinicalTrials.gov Identifier:
NCT04919733
Other Study ID Numbers:
  • 2019-3060
First Posted:
Jun 9, 2021
Last Update Posted:
May 26, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Université de Sherbrooke
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2022